A Phase II/III, multi-center, open-label, extension study to determine the long-term safety, tolerability, and efficacy of evenamide in patients with psychiatric disorders who participated in a previous trial with evenamide
Latest Information Update: 03 Mar 2022
At a glance
- Drugs Evenamide (Primary)
- Indications Bipolar disorders; Psychiatric disorders; Schizophrenia
- Focus Therapeutic Use
- Acronyms Evenamide_020
- Sponsors Newron Pharmaceuticals
Most Recent Events
- 03 Mar 2022 New trial record